Today's Low
₹ 1,020.15
Today's High
₹ 1,039.45
52 Weeks Low
₹ 348.50
52 Weeks High
₹ 615.35
Lower
₹ 923.80
Upper
₹ 1,129.00
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 9,873.7 | 8,282.4 | 7,359.6 | 6,803.6 | 6,696.8 | 6,988.7 | 6,874.6 | 5,904.3 | 5,331.1 | 4,762.7 | 3,726.8 | 2,947.2 | 2,598.8 | 2,421.1 | 2,079.1 | 1,651.0 | 1,105.4 |
Total Non-Current Assets | 7,692.0 | 7,114.8 | 6,709.3 | 6,425.5 | 5,209.0 | 4,286.4 | 3,578.0 | 3,223.7 | 2,978.0 | 3,149.6 | 2,887.1 | 2,518.9 | 2,243.2 | 2,406.2 | 2,129.8 | 1,274.6 | 829.2 |
Total Assets | 17,565.8 | 15,397.2 | 14,068.9 | 13,229.1 | 11,905.8 | 11,275.1 | 10,452.6 | 9,128.0 | 8,309.1 | 7,912.3 | 6,613.9 | 5,466.0 | 4,842.0 | 4,827.3 | 4,208.9 | 2,925.6 | 1,934.6 |
Total Current Liabilities | 5,045.5 | 4,689.4 | 4,201.0 | 4,126.0 | 4,021.1 | 3,287.9 | 2,702.7 | 3,999.3 | 3,776.7 | 2,949.2 | 2,201.4 | 1,901.7 | 2,259.1 | 518.6 | 456.3 | 320.7 | 239.5 |
Total Non-Current Liabilities | 2,681.0 | 1,269.6 | 2,803.6 | 3,033.0 | 2,279.9 | 2,824.1 | 3,257.8 | 1,499.4 | 2,749.1 | 1,966.6 | 1,625.1 | 1,137.6 | 519.0 | 1,940.4 | 2,151.3 | 1,085.5 | 1,008.7 |
Shareholder's Funds | 9,473.9 | 9,086.7 | 7,064.6 | 6,070.5 | 5,605.2 | 5,163.5 | 4,492.5 | 3,629.6 | 1,783.5 | 2,983.3 | 2,763.0 | 2,401.6 | 2,037.2 | 2,355.2 | 1,598.2 | 1,517.9 | 686.4 |
Total Liabilities | 17,565.8 | 15,397.2 | 14,068.9 | 13,229.1 | 11,905.8 | 11,275.1 | 10,452.6 | 9,128.0 | 8,309.1 | 7,912.3 | 6,613.9 | 5,466.0 | 4,842.0 | 4,827.3 | 4,208.9 | 2,925.6 | 1,934.6 |
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 1.13, which results in a Negative aspect.
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 0.80, which results in a Negative aspect.
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 1.65, which results in a Negative aspect.
The Industry Price to BV stands at 6.03, vs the Price to BV of 3.26, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 12,990.1 | 12,304.9 | 10,943.9 | 10,641.0 | 9,865.5 | 9,074.4 | 9,079.4 | 7,561.7 | 6,680.9 | 5,945.0 | 4,969.1 | 4,020.6 | 2,949.1 | 2,480.5 | 2,086.5 | 1,975.7 | 1,222.0 |
Total Expenditure | 10,711.7 | 9,984.6 | 8,859.6 | 8,942.9 | 8,279.7 | 7,459.1 | 7,042.7 | 6,124.5 | 5,466.6 | 4,854.2 | 3,953.9 | 3,306.3 | 2,356.8 | 1,860.9 | 1,631.5 | 1,175.2 | 795.8 |
Operating Profit(Excl OI) | 2,595.2 | 2,487.0 | 2,134.6 | 1,857.7 | 1,793.9 | 1,706.8 | 2,074.1 | 1,457.2 | 1,221.2 | 1,102.3 | 1,026.0 | 732.5 | 736.7 | 670.0 | 634.2 | 854.2 | 443.4 |
Add: Other Income | 316.8 | 166.7 | 50.2 | 159.6 | 208.1 | 91.4 | 37.4 | 20.0 | 6.9 | 11.5 | 10.8 | 18.2 | 144.4 | 50.5 | 179.3 | 53.7 | 17.1 |
Operating Profit | 2,595.2 | 2,487.0 | 2,134.6 | 1,857.7 | 1,793.9 | 1,706.8 | 2,074.1 | 1,457.2 | 1,221.2 | 1,102.3 | 1,026.0 | 732.5 | 736.7 | 670.0 | 634.2 | 854.2 | 443.4 |
Less: Interest | 349.6 | 298.1 | 353.1 | 377.3 | 334.6 | 285.6 | 237.3 | 178.9 | 190.2 | 188.6 | 160.0 | 146.6 | 160.5 | 165.5 | 145.7 | 71.0 | 39.8 |
PBDT | 2,245.6 | 2,188.9 | 1,781.5 | 1,480.4 | 1,459.4 | 1,421.2 | 1,836.8 | 1,278.3 | 1,031.0 | 913.7 | 866.0 | 586.0 | 576.2 | 504.5 | 488.5 | 783.2 | 403.6 |
Less: Depreciation Amortization | 611.3 | 486.7 | 443.6 | 417.2 | 325.9 | 301.9 | 264.4 | 234.3 | 300.4 | 216.8 | 127.0 | 97.9 | 94.7 | 120.6 | 102.7 | 71.7 | 42.3 |
PBT & Exceptional Items | 1,634.3 | 1,702.2 | 1,337.9 | 1,063.2 | 1,133.5 | 1,119.3 | 1,572.4 | 1,044.0 | 730.6 | 696.9 | 739.0 | 488.1 | 481.5 | 383.9 | 385.8 | 711.5 | 361.3 |
Less: Exceptional Income Expenses | -765.9 | -260.9 | 44.6 | 32.9 | 167.2 | 0.0 | -81.0 | 0.0 | -187.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -117.0 | 0.0 | 0.0 |
Profit Before Tax | 868.5 | 1,441.3 | 1,382.5 | 1,096.1 | 1,300.6 | 1,119.3 | 1,491.4 | 1,044.0 | 543.6 | 696.9 | 739.0 | 488.1 | 481.5 | 383.9 | 268.9 | 711.5 | 361.3 |
Less: Taxation | 491.1 | 447.6 | 412.4 | 320.1 | 375.6 | 315.5 | 382.7 | 300.9 | 334.1 | 151.3 | 110.7 | 23.8 | 23.7 | 52.9 | 75.4 | 79.4 | 51.3 |
Profit After Tax | 377.4 | 993.7 | 970.1 | 776.0 | 925.0 | 803.9 | 1,108.8 | 743.1 | 209.5 | 545.6 | 628.3 | 464.3 | 457.8 | 331.0 | 193.5 | 632.1 | 310.1 |
Earnings Per Share | 1.1 | 3.3 | 3.4 | 2.8 | 3.3 | 2.9 | 3.9 | 2.6 | 0.8 | 2.0 | 2.3 | 1.7 | 1.7 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry PAT Margin stands at 9.75, vs the PAT Margin of 7.29, which results in a Negative aspect.
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 0.24, which results in a Negative aspect.
The Industry PAT Growth stands at 32.19, vs the PAT Growth of -16.11, which results in a Negative aspect.
The Industry PE Ratio stands at 42.56, vs the PE Ratio of 0.00, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 868.5 | 1,441.2 | 1,382.5 | 1,096.1 | 1,300.6 | 1,119.3 | 1,491.4 | 1,044.0 | 543.5 | 696.9 | 739.0 | 488.1 | 481.6 | 383.9 | 268.9 | 711.5 | 361.3 |
Tax Paid | -640.5 | -558.4 | -510.2 | -467.0 | -442.6 | -351.6 | -699.0 | -478.2 | -317.8 | -262.9 | -165.0 | -133.0 | -93.8 | -87.4 | -139.5 | -88.5 | -27.7 |
Adjustment | 1,472.0 | 787.1 | 644.8 | 636.2 | 329.8 | 571.3 | 726.6 | 391.0 | 522.8 | 709.8 | 342.4 | 484.1 | 189.7 | 265.3 | 274.1 | 133.4 | 85.9 |
Changes In Working Capital | 868.5 | 1,441.2 | 1,382.5 | 1,096.1 | 1,300.6 | 1,119.3 | 1,491.4 | 1,044.0 | 543.5 | 696.9 | 739.0 | 488.1 | 481.6 | 383.9 | 268.9 | 711.5 | 361.3 |
Cash Flow after changes in Working Capital | 1,265.9 | 1,667.1 | 1,641.5 | 1,859.4 | 1,766.8 | 1,999.7 | 1,356.5 | 823.0 | 799.5 | 1,116.6 | 813.0 | 937.3 | 1,024.3 | 439.8 | 155.4 | 460.3 | 120.9 |
Cash Flow from Operating Activities | 625.4 | 1,108.7 | 1,131.2 | 1,392.4 | 1,324.2 | 1,648.1 | 657.4 | 344.8 | 481.7 | 853.7 | 647.9 | 804.4 | 930.6 | 352.4 | 15.9 | 371.8 | 93.2 |
Cash Flow from Investing Activities | -528.5 | -333.3 | -675.2 | -783.5 | -699.0 | -1,013.3 | -712.3 | -880.2 | -540.0 | -368.1 | -464.1 | -277.8 | -367.3 | -386.9 | -950.2 | -509.6 | -268.8 |
Cash Flow from Financing Activities | -77.5 | -520.5 | -441.8 | -444.7 | -738.7 | -468.5 | 543.2 | 698.6 | 199.2 | -98.0 | 195.2 | -361.4 | -435.6 | 70.0 | 849.2 | 188.6 | 175.7 |
Net Cash Inflow / Outflow | 19.4 | 254.9 | 14.2 | 164.2 | -113.6 | 166.2 | 488.2 | 163.3 | 140.9 | 387.6 | 379.1 | 165.2 | 127.7 | 35.5 | -85.0 | 50.8 | 0.2 |
Opening Cash & Cash Equivalents | 1,410.5 | 1,138.1 | 1,110.3 | 936.3 | 1,233.4 | 1,056.4 | 857.1 | 763.7 | 794.8 | 605.2 | 320.1 | 194.9 | 103.6 | 71.5 | 156.5 | 105.8 | 105.6 |
Closing Cash & Cash Equivalent | 1,443.0 | 1,410.5 | 1,138.1 | 1,110.3 | 936.3 | 1,233.4 | 1,056.4 | 857.1 | 763.7 | 794.8 | 605.2 | 320.1 | 194.9 | 107.0 | 71.5 | 156.5 | 105.8 |
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of 14.95, which results in a Negative aspect.
The Industry PCF RATIO stands at 24.29, vs the PCF RATIO of 4.18, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 25,067.0 | 32,073.8 | 34,016.0 | 33,737.2 | 34,638.6 | 33,752.5 | 27,772.9 | 30,191.5 | 31,734.1 | 31,474.5 | 29,649.0 | 28,599.0 | 27,867.6 | 29,524.8 | 23,447.9 | 27,674.9 |
Total Income | 25,521.1 | 32,090.8 | 34,224.8 | 33,335.0 | 35,402.7 | 34,726.8 | 29,604.4 | 31,263.5 | 31,873.1 | 31,343.8 | 30,235.4 | 28,683.9 | 28,018.5 | 29,206.0 | 24,033.0 | 28,116.3 |
Total Expenditure | 27,153.5 | 27,450.9 | 27,703.9 | 27,687.5 | 28,436.1 | 27,536.9 | 23,456.9 | 25,557.5 | 24,802.6 | 25,572.8 | 23,913.2 | 23,364.7 | 22,566.9 | 23,996.7 | 18,667.2 | 23,018.0 |
PBIDT (Excl OI) | -2,086.5 | 4,622.9 | 6,312.1 | 6,049.7 | 6,202.5 | 6,215.6 | 4,316.0 | 4,634.0 | 6,931.5 | 5,901.7 | 5,735.8 | 5,234.3 | 5,300.7 | 5,528.1 | 4,780.7 | 4,656.9 |
Other Income | 454.1 | 17.0 | 208.7 | -402.1 | 764.2 | 974.3 | 1,831.6 | 1,072.0 | 139.0 | -130.7 | 586.5 | 84.9 | 150.9 | -318.8 | 585.1 | 441.5 |
Operating Profit | -1,632.4 | 4,639.8 | 6,520.9 | 5,647.5 | 6,966.6 | 7,189.9 | 6,147.6 | 5,706.0 | 7,070.5 | 5,771.0 | 6,322.3 | 5,319.2 | 5,451.6 | 5,209.3 | 5,365.8 | 5,098.3 |
Interest | 1,343.4 | 1,214.6 | 1,120.0 | 1,092.6 | 972.7 | 830.7 | 599.9 | 868.5 | 667.0 | 689.5 | 756.0 | 833.3 | 954.1 | 806.3 | 937.4 | 984.7 |
Exceptional Items | -767.2 | -3,254.2 | -520.2 | -7,997.3 | 338.8 | 0.0 | 0.0 | -825.3 | -1,783.8 | 0.0 | 0.0 | 0.0 | 134.2 | 31.4 | 279.9 | 328.8 |
PBDT | -3,743.1 | 171.0 | 4,880.6 | -3,442.4 | 6,332.7 | 6,359.2 | 5,547.7 | 4,012.2 | 4,619.7 | 5,081.5 | 5,566.2 | 4,485.9 | 4,631.7 | 4,434.4 | 4,708.3 | 4,442.3 |
Depreciation | 1,470.8 | 1,414.5 | 1,546.5 | 1,465.3 | 1,622.8 | 1,557.1 | 1,467.6 | 1,315.2 | 1,189.3 | 1,231.9 | 1,130.7 | 1,110.7 | 1,152.0 | 1,040.7 | 1,132.2 | 1,262.8 |
Profit Before Tax | -5,213.8 | -1,243.5 | 3,334.1 | -4,907.7 | 4,710.0 | 4,802.1 | 4,080.1 | 2,696.9 | 3,430.4 | 3,849.6 | 4,435.5 | 3,375.2 | 3,479.7 | 3,393.8 | 3,576.1 | 3,179.6 |
Tax | -718.0 | 559.5 | 1,602.8 | -876.3 | 1,802.3 | 2,015.4 | 1,969.1 | 971.3 | 1,032.9 | 1,101.6 | 1,370.3 | 1,036.5 | 997.9 | 1,053.8 | 1,035.7 | 976.5 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | -4,495.8 | -1,803.0 | 1,731.3 | -4,031.4 | 2,907.6 | 2,786.7 | 2,111.1 | 1,725.7 | 2,397.5 | 2,748.1 | 3,065.3 | 2,338.7 | 2,481.8 | 2,339.9 | 2,540.4 | 2,203.1 |
Net Profit | -3,308.2 | -615.6 | 1,731.3 | -4,031.4 | 2,907.6 | 2,786.7 | 2,111.1 | 1,725.7 | 2,397.5 | 2,748.1 | 3,065.3 | 2,338.7 | 2,481.8 | 2,339.9 | 2,540.4 | 2,203.1 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 | 282.2 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | -16.7 | -7.1 | 5.3 | -15.2 | 9.7 | 9.2 | 6.8 | 5.5 | 7.9 | 9.1 | 10.9 | 8.3 | 8.8 | 8.3 | 9.0 | 7.8 |
Operating Profit Margin | -6.5 | 14.5 | 19.2 | 16.7 | 20.1 | 21.3 | 22.1 | 18.9 | 22.3 | 18.3 | 21.3 | 18.6 | 19.6 | 17.6 | 22.9 | 18.4 |
Net Profit Margin | -17.9 | -5.6 | 5.1 | -11.9 | 8.4 | 8.3 | 7.6 | 5.7 | 7.6 | 8.7 | 10.3 | 8.2 | 8.9 | 7.9 | 10.8 | 8.0 |
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of 7.86, which results in a Negative aspect.
The Industry Mcap Growth stands at 19.69, vs the Mcap Growth of -68.08, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 1,065.00 | 1,086.00 | 1,037.02 |
R3 | 1,056.48 | 1,055.35 | 1,031.71 |
R2 | 1,047.97 | 1,047.40 | 1,029.94 |
R1 | 1,037.18 | 1,036.05 | 1,028.17 |
Pivot | 1,028.67 | 1,028.10 | 1,028.67 |
S1 | 1,017.88 | 1,016.75 | 1,024.63 |
S2 | 1,009.37 | 1,008.80 | 1,022.86 |
S3 | 998.58 | 997.45 | 1,021.09 |
S4 | 987.80 | 970.20 | 1,015.79 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
0.00
Bullish
RSI
63.17
Neutral
ROC
3.99
Bullish
UltimateOscillator
50.42
Neutral
Williams Indicator
-37.67
Neutral
CCI Indicator
48.08
Neutral
MACD
-2,195.91
Bearish
Stochastic Indicator
68.58
Neutral
ATR
26.92
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|---|---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|---|---|---|
18-09-2023 | 2.50 | 250 | Final |
08-09-2021 | 2.50 | 250 | Final |
Date Of Conduct | Board Meeting Details |
---|---|
14-02-2024 | Quarterly Results |
10-11-2023 | Quarterly Results |
11-08-2023 | Quarterly Results |
19-05-2023 | Final Dividend & Audited Results |
10-02-2023 | Quarterly Results |
11-11-2022 | Quarterly Results |
10-08-2022 | Quarterly Results |
27-05-2022 | Final Dividend & Audited Results & Quarterly Results |
11-02-2022 | Quarterly Results |
12-11-2021 | Quarterly Results |
13-08-2021 | Quarterly Results |
28-05-2021 | Quarterly Results & Final Dividend & Audited Results |